The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
FDA Fast Tracks BCMA-Targeted CAR T-Cell Therapy for R/R Multiple Myeloma
April 8th 2023The FDA has granted a fast track designation to CB-011, a CRISPR-edited allogeneic CAR T-cell therapy developed by Caribou Biosciences, for the treatment of patients with relapsed/refractory multiple myeloma.
Read More
Characteristics of Relapse Affect Treatment Choices in Multiple Myeloma
April 3rd 2023Natalie S. Callander, MD, director of the University of Wisconsin Carbone Cancer Center Myeloma Clinical Program, reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.
Read More
Ide-Cel Shows Benefit vs Standard Regimens in Heavily Pretreated R/R Multiple Myeloma
March 30th 2023Idecabtagene vicleucel (ide-cel) led to significantly longer PFS and better therapy responses than standard regimens for patients with triple-class–exposed relapsed and refractory multiple myeloma.
Read More
Study Characterizes Infections in Patients Treated With Bispecific Antibodies for Multiple Myeloma
March 23rd 2023A recent study found that infection is a significant burden in patients with multiple myeloma who receive bispecific antibodies, and viral infections are the most common culprits.
Read More
Dr Ajai Chari: Patients in High-risk Subgroups Benefited From Daratumumab Plus Triplet
March 9th 2023Ajai Chari, MD, professor of medicine and director of clinical research in the Multiple Myeloma Program at Mount Sinai in New York, discusses a post-hoc analysis of data from the phase 2 GRIFFIN trial.
Read More
Screening Protocols During Early Phase of COVID-19 Improved Outcomes in MM
March 6th 2023Researchers retrospectively analyzed data from patients who visited 2 myeloma centers between March and October 2020, before vaccines were widely available but during large-scale implementation of regular screening processes.
Read More
Diagnosis of Second Primary Malignancies Associated With Prolonged Survival Among Patients With MM
March 3rd 2023Incidences of certain second primary malignancies were associated with increased overall survival among patients with multiple myeloma in a retrospective analysis of real-world data.
Read More
Population-Based Study Finds Increased Risk of Stroke, Heart Attack in Patients With MM
February 23rd 2023Individuals with multiple myeloma were 51% more likely to have a stroke and 36% more likely to have a heart attack compared with the general patient population in a large real-world assessment of arterial thrombotic events among patients with multiple myeloma in the United States.
Read More
Cases of SCC-Related Hospitalizations Increasing Among Patients With Multiple Myeloma
February 15th 2023Throughout this study's 12-year period, the average annual percent change showed an uptrend for all groups in hospitalization for spinal cord compression (SCC), and this was higher for non-Hispanic Black patients vs Hispanic patients and non-Hispanic White patients.
Read More
Including MRD Status Reduces Uncertainty in Long-term Survival Models of NDMM
February 3rd 2023Having models like these that produce more plausible results are crucial for decision-making in an era of targeted treatments that often come with immature data, argued researchers of their findings for minimal residual disease (MRD) in newly diagnosed multiple myeloma (NDMM).
Read More
An interview with Joseph R. Mikhael, MD, MEd, on findings from a Quality Improvement initiative presented during the 64th American Society of Hematology Annual Meeting and Exposition in New Orleans, Louisiana. Mikhael is a professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute, an affiliate of City of Hope Cancer Center, in Phoenix, Arizona.
Read More
Spotlighting Health Disparities for Black Americans With Multiple Myeloma and Potential Solutions
January 11th 2023Black Americans with multiple myeloma face disparities in incidence of disease, survival outcomes, and use of evidence-based treatment, which may be exacerbated by socioeconomic factors.
Read More
Disparities in Multiple Myeloma Treatment, Mortality Risk Observed Among Hispanic Americans
January 9th 2023Despite greater incidence of multiple myeloma (MM) reported among Hispanic Americans, these populations report less MM maintenance therapy, longer time from MM diagnosis to novel therapy initiation, and higher in-hospital mortality rates.
Read More